BridgeBio Oncology Therapeutics, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data BridgeBio Oncology Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Research and development
73.1
121
General and administrative
0.04
7.76
24.6
Operating expenses
80.9
146
Operating income
-0.04
-80.9
-146
Interest income
8.45
Other non-operating income
6.59
11.8
Income tax
0
0
Net income
-0.04
-74.3
-134
EBITDA
-80.7
-146
EPS, basic
-5,756.00
-4.30
EPS, diluted
-5,756.00
-4.30
Shares, basic (weighted)
0.01
31.1
Shares, diluted (weighted)
0.01
31.1
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
0.25
30.9
374
Short-term investments
125
51.8
Other current assets
2.98
6.55
Total current assets
159
432
Property, plant and equipment
0.49
0.96
Lease right-of-use assets
0
2.33
Long-term investments
0
Other non-current assets
4.99
12.6
Total assets
0.33
164
448
Accounts payable
3.07
1.37
Accrued liabilities
0.02
0.12
Total current liabilities
0.4
19.6
35
Lease liabilities
0
2.24
Total liabilities
0.4
19.6
37.3
Paid-in capital
0.02
43.5
768
Retained earnings
-0.09
-223
-357
Other comprehensive income
0.35
0.02
Shareholders' equity
-116
-179
411
Total equity
-116
-179
411
Total liabilities and equity
0.33
164
448
Shares outstanding
0.03
80
Cash flow statement
FY2024
FY2024
FY2025
Net income
-0.04
-74.3
-134
Depreciation and amortization
0.21
0.28
Stock-based compensation
4.43
5.87
Deferred income tax
0
0
Change in payables
0.02
2.5
-1.84
Cash from operations
-55
-114
Capital expenditures
-0.05
-0.61
Purchases of investments
-154
-83.9
Sales and maturities of investments
31.5
158
Cash from investing
-121
73.3
Stock issued
0.05
112
Cash from financing
206
383
Net change in cash
30.7
343
Free cash flow
-55.1
-115
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.95 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-56.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-48.3%
Net income / average total assets.
Return on invested capital (ROIC)
-58.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
172.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
241,276.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.69x
Current assets / current liabilities.
Quick ratio
4.37x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.37x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.89
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.89
Cash from operations / diluted weighted shares.
Book value per share
$4.03
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.98x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.98x
Market cap / tangible book value, when positive.
FCF yield
-47.9%
Free cash flow / market cap.
Earnings yield
-57.5%
Net income / market cap (the inverse of P/E).
Was BridgeBio Oncology Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $134.0M.
How much free cash flow did BridgeBio Oncology Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $113.9M minus capital expenditures of $606.0K left free cash flow of -$114.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.